RxDoctor Payments Data

Steven Obrien, MD

Internal Medicine · Glenwood Springs, CONPI 1174623193

Payments from drug & device makers

$2,019in general payments, 2019–2025

Across 84 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370
  • Novartis$221
  • Sanofi-aventis U.S. LLC$196
  • Medtronic$170
  • Amgen$142
  • SK Life Science, Inc.$109
  • plus $811 from 19 others

What the payments were for

  • Food & beverage$2,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,019 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$223,904
Medicare patients
314
Services billed
4,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$53,529
MounjaroTirzepatide31$48,594
JardianceEmpagliflozin31$40,723
TrulicityDulaglutide28$35,005
OzempicSemaglutide25$26,066
Repatha SureclickEvolocumab17$18,770
XareltoRivaroxaban31$17,729
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$10,503
GemtesaVibegron31$10,002
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$7,451
LinzessLinaclotide14$7,354
ArexvyRsvpref3 Antigen/As01e/Pf12$3,510
Estradiol35$2,895
Duloxetine Hcl97$2,479
Atorvastatin Calcium249$2,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$107$83,59959 claims
PfizerEliquis$69$53,52935 claims
Johnson & JohnsonXarelto$39$17,72931 claims
Sumitomo Pharma America, Inc.Gemtesa$20$10,00231 claims
AbbVieLinzess, Synthroid$370$8,08432 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$49$997137 claims
ANI Pharmaceuticals, Inc.Valsartan$21$81225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Glenwood Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →